* Shasun Pharmaceuticals falls 6 percent after its
Vertex Pharmaceuticals warned on Wednesday its
hepatitis C drug Incivek, which is used in conjunction with two
other products, can cause serious, potentially fatal skin
* Shasun has a long-term agreement with Vertex for supply of
active pharmaceutical ingredient for the Hepatitis C drug.
* "There would be incremental impact on Shasun as about 25
percent of FY13 profits were expected to come in from Incivek
supply," said Surya Patra, an analyst tracking the sector at
Systematix Shares & Stocks.